IDH1 and glioblastoma: Improving outcomes for people diagnosed with glioblastoma (GBM), IDH-wildtype (IDHwt), the most common and lethal primary brain tumour in adults, requires the development of sensitive methods that efficiently and sensitively monitor tumour activity and treatment response.